TABLE 1.
Characteristic | Value for patients with treatment: |
Pb | |
---|---|---|---|
Failure (n = 12)a | Remission (n = 35) | ||
Median (IQR) age (yr) | 71 (64.2-79) | 75 (63-79) | 0.96 |
No. (%) female | 7 (58.3) | 24 (68.3) | 0.37 |
No. (%) of patients with a comorbidityc | 6 (50) | 15 (42.9) | 0.46 |
No. (%) of patients with the following type of prosthesis: | |||
Hip | 4 (33.5) | 11 (31.4) | |
Knee | 8 (66.7) | 24 (68.6) | 0.58 |
Median (IQR) age of prosthesis (days) | 19 (17.2-22.7) | 21 (13-31) | 0.71 |
No. (%) of patients with the following type of infection: | |||
Postsurgical | 12 | 32 (91.4) | |
Hematogenous | 0 | 3 (8.6) | 0.40 |
Median (IQR) leukocyte count (no. of cells/mm3) | 8,750 (4,925-11,122) | 8,100 (6,150-10,417) | 0.97 |
Median (IQR) CRP concn (mg/dl) | 11.4 (1.4-21.4) | 4.2 (0.8-12.9) | 0.20 |
No. (%) of patients with: | |||
CRP concn of >15 mg/dl | 6 (50) | 6 (17.1) | 0.03 |
Bacteremia | 0 | 4 (11.4) | 0.29 |
Polymicrobial infection | 7 (58.3) | 21 (60) | 0.59 |
Mixed infection with gram-positive organisms | 3 (25) | 15 (42.9) | 0.32 |
Infection due to a Pseudomonas sp.d | 4 (33.5) | 16 (45.7) | 0.34 |
Infection due to a fluoroquinolone-resistant strain | 8 (66.7) | 5 (14.3) | 0.001 |
Infection due to an ESBL-producing member of Enterobacteriaceae family | 4 (33.3) | 4 (11.4) | 0.17 |
Need for a second debridement | 3 (25) | 4 (11.4) | 0.24 |
Median (IQR) duration of antibiotic therapy (oral and intravenous) (days) | 84.5 (35.5-167.2) | 82 (47-135) | 0.94 |
Median (IQR) duration of oral antibiotic therapy (days)e | 95 (27.7-165.2) | 64 (36-101.5) | 0.46 |
No. (%) of patients treated with fluoroquinolones | 7 (58.3) | 28 (80) | 0.13 |
No. (%) of patients treated with fluoroquinolones when all isolated GNB were susceptible | 2 (16.7) | 26 (74.3) | 0.001 |
Including relapse and reinfection.
Mann-Whitney U test, χ2 test, or Fisher exact test, when necessary.
Diabetes mellitus, liver cirrhosis, chronic renal failure, rheumatoid arthritis, or chronic obstructive pulmonary disease.
P. aeruginosa in 19 cases and Pseudomonas stutzeri in 1 case.
The information is for those patients who received oral antibiotics (n = 41).